Inhibition of cytochrome P450 enzymes by the E-and Z-isomers of norendoxifen

Drug Metabolism and Disposition

Volumn 41, Issue 9, 2013, Pages 1715-1720

  Liu, Jinzhong ^a   Flockhart, Peter J ^a   Lu, Deshun ^a   Lv, Wei ^b   Lu, Wenjie Jessie ^a   Han, Xu ^a   Cushman, Mark ^b   Flockhart, David A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; NORENDOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; ISOMER; MICROSOME; MOLECULAR DYNAMICS; PRIORITY JOURNAL;

AROMATASE INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; STEREOISOMERISM; TAMOXIFEN;

EID: 84882787119     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.052506     Document Type: Article

References (27)

1. Del Re M, Michelucci A, Simi P, and Danesi R (2012) Pharmacogenetics of anti-estrogen treatment of breast cancer. Cancer Treat Rev 38:442-450.
2. Desta Z, Kreutz Y, Nguyen AT, Li L, Skaar T, Kamdem LK, Henry NL, Hayes DF, Storniolo AM, and Stearns V, et al. (2011) Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther 90:693-700.
3. Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, and Hall E (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 24:910-917.
4. Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, and Nussbaum R, et al.; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use (2008) Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 10:139-150.
5. Foti RS and Wahlstrom JL (2008) CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos 36:523-528.
6. Giobbie-Hurder A, Price KN, and Gelber RD (2009) Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials 6:272-287.
7. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, and Tobias JS (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62.
8. Jeong S, Woo MM, Flockhart DA, and Desta Z (2009) Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,49-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol 64:867-875.
9. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, and Araba A, et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39.
10. Kamdem LK, Flockhart DA, and Desta Z (2011) In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos 39:98-105.
11. Lien EA, Wester K, Lønning PE, Solheim E, and Ueland PM (1991) Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer 63: 641-645.
12. Lim YC, Desta Z, Flockhart DA, and Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-Tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-Tamoxifen. Cancer Chemother Pharmacol 55:471-478.
13. Lu WJ, Desta Z, and Flockhart DA (2012a) Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res Treat 131:473-481.
14. Lu WJ, Ferlito V, Xu C, Flockhart DA, and Caccamese S (2011) Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms. Chirality 23:891-896.
15. Lu WJ, Xu C, Pei ZF, Mayhoub AS, Cushman M, and Flockhart DA (2012b) The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res Treat 133:99-109.
16. Pearson JT, Wahlstrom JL, Dickmann LJ, Kumar S, Halpert JR, Wienkers LC, Foti RS, and Rock DA (2007) Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chem Res Toxicol 20:1778-1786.
17. Pickar JH, MacNeil T, and Ohleth K (2010) SERMs: progress and future perspectives. Maturitas 67:129-138.
18. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448.
19. Ridderström M, Zamora I, Fjellström O, and Andersson TB (2001) Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. J Med Chem 44:4072-4081.
20. Santoro S, Santini M, Pepe CA, Tognetti E, Cortelazzi C, Ficarelli E, and De Panfilis G (2011) Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis. J Eur Acad Dermatol Venereol 25:596-598.
21. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, and Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764.
22. Subbaramaiah K, Hudis C, Chang S-H, Hla T, and Dannenberg AJ (2008) EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem 283:3433-3444.
23. Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, and Latif A, et al. (2011) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125:279-287.
24. Ward BA, Morocho A, Kandil A, Galinsky RE, Flockhart DA, and Desta Z (2004) Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 58:277-287.
25. Yu K-D, Zhou Y, Liu G-Y, Li B, He P-Q, Zhang H-W, Lou L-H, Wang X-J, Wang S, and Tang J-H, et al. (2012) A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Breast Cancer Res Treat 134:307-313.
26. Zhou S-F, Wang B, Yang L-P, and Liu J-P (2010) Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 42: 268-354.
27. Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, and Hadji P (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20: 431-436.